Tag
A pivotal Phase 2 study demonstrates that derazantinib yields meaningful responses and progression-free survival in FGFR2-aberrant advanced intrahepatic cholangiocarcinoma, with an acceptable safety profile, supporting its role as a targete
This review synthesizes phase 3 clinical evidence comparing divarasib, sotorasib, and adagrasib for KRAS G12C-mutated NSCLC, highlighting divarasib’s superior efficacy and safety, dose optimization insights, real-world data, and trans
The phase 3 SAFFRON trial demonstrated that osimertinib combined with savolitinib significantly improves progression-free and overall survival versus platinum-pemetrexed chemotherapy in advanced EGFR-mutated NSCLC harboring MET overexpressi
PPM1D mutations and overexpression are involved in MPN pathogenesis, with dual PPM1D and HDM2 inhibition emerging as a promising therapeutic strategy, particularly for myelofibrosis patients.
Telomere length serves as an independent prognostic marker for progression-free survival in chronic lymphocytic leukemia patients treated with venetoclax-based regimens, highlighting its role in risk stratification during the modern targete
A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies
A 50-year-old woman with metastatic medullary thyroid carcinoma (MTC) lacking RET alterations exhibited a remarkable sustained response to selpercatinib, suggesting potential efficacy beyond RET-mutated cases.
This article explores the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a promising targeted therapy that degrades oncogenic NSD2 in t(4;14) multiple myeloma, reversing malignant epigenomic programs and improving disease outcomes i
This article highlights the discovery that TYK2 kinase is a selective therapeutic target in CALR-mutant myeloproliferative neoplasms, with combined TYK2 and JAK2 inhibition offering enhanced efficacy over JAK2 inhibition alone.
This study identifies an IL-17A/PTGS2/NLRP3 signaling axis as a key driver of immune suppression and myeloproliferation in PTPN11-mutant JMML, demonstrating that combined inflammasome and PTGS2 inhibition with MEK blockade improves survival
PKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.
A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients
Bendamustine monotherapy achieved high response rates and inhibited STAT3 signaling in patients with high burden T-cell large granular lymphocytic leukemia, showing promise as an effective and well-tolerated treatment option.
Cheminformatic screening identified novel small molecules with apoptotic, autophagic, and reductase-inhibitory activities that selectively kill AML cells, induce mitochondrial dysfunction, and synergize with current therapies, highlighting
Ivosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.
Comprehensive proteomic and phosphoproteomic profiling of 267 neuroendocrine carcinomas across multiple tissues reveals distinct molecular subtypes, biomarkers, and a novel NAD+ metabolic vulnerability, advancing personalized precision medi
Erythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control r
This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.
Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.
KRAS mutation and high glucose promote O-GlcNAcylation of CLDN18.2 in pancreatic cancer, pushing the protein off the cell membrane, boosting metastasis, and weakening CLDN18.2-targeted therapy. Low-dose MRTX1133 may restore sensitivity.
